Project Grant R01MH143822
- The National Institute of Mental Health awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $839,023 on April 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and validate computer vision techniques for suicide risk detection in emergency department settings. The award funds development of automated analysis of standardized skin images to identify and assess the severity of self-injury marks as predictors of prospective...
- The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $790,560 under the Mental Health Research Grants program (CFDA 93.242) on April 1, 2026. The award funds development of advanced artificial intelligence models to predict differential antidepressant treatment responses by integrating electronic health records and genomic data. Aim 1 involves building a large language model-based, human-in-the-loop active learning framework to...
- The National Institute of Mental Health awarded Massachusetts General Hospital $197,578 on June 1, 2026, under the Mental Health Research Grants program (CFDA 93.242, K23MH144215) to investigate sleep and circadian timing irregularities as short-term risk factors for adolescent suicide through intensive longitudinal study. The research recruits 100 adolescents hospitalized for suicidal thoughts and behaviors, continuously monitoring objective sleep metrics via wrist actigraphy and collecting...
- The National Institute of Mental Health awarded Wellesley College $707,584 under the Mental Health Research Grants program (CFDA 93.242) on August 1, 2026, to develop machine learning models that encode clinical knowledge for understanding, prediction, and prevention of suicide. The project addresses three data analysis bottlenecks in ecological momentary assessment studies of suicidal thoughts and behaviors: small sample sizes that limit deep learning applications, stochasticity in external...
- The National Institute of Mental Health awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $453,750 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and test an optimized case management intervention for people living with HIV who face barriers to adherence to care. The project, titled the OPTI-HEAT Study, will develop a multi-level case management implementation toolkit designed to improve viral suppression...
- The National Institute of Mental Health awarded the University of California, San Diego $199,271 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop a measurement-informed machine learning model for generalizable suicide risk prediction in youth. The project will create a transparent, interpretable, and developmentally sensitive machine learning model incorporating neurobiological, psychological, electronic health record-derived, and social indicators to...
- The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $765,876 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct advanced neuroimaging research on subcortical brain dynamics during human sleep. The recipient will use high-resolution 7-Tesla functional magnetic resonance imaging and simultaneous electroencephalography with a novel ultra-high-field compatible net to map circuit activity in the...
- The National Institute of Mental Health awarded Beth Israel Deaconess Medical Center, Inc. $2.961 million on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop standardized digital health data formats for mental health research and clinical care. The award funds five integrated aims. Aim 1 establishes a multidisciplinary consortium of clinicians, researchers, industry representatives, regulators, and patient advocates to develop a governance framework...
- The National Institute of Mental Health awarded Massachusetts General Hospital $453,750 under the Mental Health Research Grants program (CFDA 93.242) on September 1, 2026, to develop a closed-loop system for assessing target network engagement using concurrent transcranial magnetic stimulation and functional MRI. The recipient is developing a flexible radiofrequency coil array (the RF Cap) that enables functional MRI acquisition simultaneously with transcranial magnetic stimulation in a...
- The National Institute of Mental Health awarded The McLean Hospital Corporation $193,320 on February 18, 2026, under the Mental Health Research Grants program (CFDA 93.242, Assistance Listing) to support a K23 mentored career development award focused on online social networking mechanisms of suicide in adolescents. The award funds research establishing objective, ecologically valid assessment of interpersonal behavior in adolescents with suicidal thoughts and behaviors (STBS) through analysis...
The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $824,404 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop machine learning models that integrate clinician-conducted suicide risk assessments with electronic health record data to improve prediction of suicidal behavior and guide precision interventions in outpatient behavioral health settings. The research leverages routine clinical suicide risk assessment (SRA) data—including clinicians' overall risk judgments, patients' documented suicidal thoughts and behaviors, and identified risk and protective factors—combined with EHR-derived information such as diagnostic codes, laboratory results, and medications. Prior work by the recipient team analyzed more than 600,000 SRAs completed at point of care in outpatient settings and achieved high accuracy (AUC=0.88) when predicting suicide attempt within six months. This award funds integration of clinician SRA features into validated EHR-based statistical models to enhance prediction accuracy and clinical utility for identifying patients requiring additional suicide prevention interventions. Place of performance is Boston, Massachusetts. The period of performance runs from September 1, 2026, through May 31, 2031. This is a Project Grant, the standard assistance type for investigator-initiated research under NIMH's mental health research portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $824.4k | 9/3/26 |